Literature DB >> 18178676

Epithelial expression of TIMP-1 does not alter sensitivity to bleomycin-induced lung injury in C57BL/6 mice.

Cheryl L Fattman1, Federica Gambelli, Gary Hoyle, Bruce R Pitt, Luis A Ortiz.   

Abstract

Matrix metalloproteinases (MMPs) are mediators of lung injury, and their activity has been associated with the development of pulmonary fibrosis. To understand how MMPs regulate the development of pulmonary fibrosis, we examined MMP expression in two strains of mice with differing sensitivities to the fibrosis-inducing drug bleomycin. After a single intratracheal injection of the drug, bleomycin-sensitive C57BL/6 mice showed increased expression for MMPs (-2, -7, -9, -13) at both 7 and 14 days posttreatment compared with the bleomycin-resistant BALB/c strain. In addition, TIMP-1, an endogenous inhibitor of MMPs, was upregulated in the lungs of C57BL/6 mice but not BALB/c mice. We designed two strategies to decrease MMP expression to potentially decrease sensitivity of C57BL/6 mice: 1) we engineered C57BL/6 mice that overexpressed TIMP-1 in their lungs via surfactant protein C (SP-C) promoter; and 2) we inhibited expression of MMPs independent of TIMP-1 by knocking out metallothionein (MT), a critical zinc binding protein. SP-C-TIMP-1 mice reduced MMP expression in response to bleomycin. However, they were equally sensitive to bleomycin as their wild-type counterparts, displaying similar levels of hydroxyproline in the lung tissue. MT null mice displayed decreased lung activity of MMPs with no change in TIMP-1. Nonetheless, there was no difference between the MT null and wild-type control littermates with regards to any of the lung injury parameters measured. We conclude that although TIMP-1 expression is differentially regulated in fibrosis-sensitive and fibrosis-resistant strains, epithelial overexpression of TIMP-1 does not appear to substantially alter fibrotic lung disease in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178676     DOI: 10.1152/ajplung.00291.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia.

Authors:  Poulami Basu; Natia Qipshidze; Suresh C Tyagi; Utpal Sen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-11-15

2.  Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury.

Authors:  Sean E Gill; Isham Huizar; Eli M Bench; Samuel W Sussman; Ying Wang; Rama Khokha; William C Parks
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

3.  Comparison of bleomycin-induced pulmonary apoptosis between NMRI mice and C57BL/6 mice.

Authors:  L Safaeian; A Jafarian-Dehkordi; M Rabbani; H M Sadeghi; N Afshar-Moghaddam; S Sarahroodi
Journal:  Res Pharm Sci       Date:  2013-01

4.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

5.  The role of mouse strain differences in the susceptibility to fibrosis: a systematic review.

Authors:  Louise Walkin; Sarah E Herrick; Angela Summers; Paul E Brenchley; Catherine M Hoff; Ron Korstanje; Peter J Margetts
Journal:  Fibrogenesis Tissue Repair       Date:  2013-09-25

6.  Phosphatidylethanolamine Induces an Antifibrotic Phenotype in Normal Human Lung Fibroblasts and Ameliorates Bleomycin-Induced Lung Fibrosis in Mice.

Authors:  Luis G Vazquez-de-Lara; Beatriz Tlatelpa-Romero; Yair Romero; Nora Fernández-Tamayo; Fernando Vazquez-de-Lara; Jaime M Justo-Janeiro; Mario Garcia-Carrasco; René de-la-Rosa Paredes; José G Cisneros-Lira; Criselda Mendoza-Milla; Francesco Moccia; Roberto Berra-Romani
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.